• Feb 14- New York Times media columnist David Carr, a beloved and widely respected journalist who wrote a memoir about his struggles with addiction, died of lung cancer and cardiovascular disease, New York City's medical examiner said on Saturday. In addition to his weekly column, Carr reported for the paper's culture section and featured prominently in "Page One:...

  • Measle-con Valley  Thursday, 12 Feb 2015 | 1:02 PM ET

    Joanna Pearlstein, Wired, provides insight to "sickeningly low" vaccination rates at day care centers across Silicon Valley.

  • UPDATE 1-Novavax starts Ebola vaccine trial in humans Thursday, 12 Feb 2015 | 12:06 PM ET

    Feb 12- Novavax Inc has begun early-stage human trials of an Ebola vaccine that it hopes can win the race to become the most effective shot for the deadly virus. The company has the means to manufacture millions of doses of the vaccine every month and is seeking funding to develop it further, Chief Executive Stanley Erck told Reuters. Even as President Barack Obama...

  • The case of the 'anti-vaccine elitism' Thursday, 12 Feb 2015 | 11:04 AM ET
    Vials of measles, mumps and rubella vaccine are displayed on a counter at a Walgreens Pharmacy on January 26, 2015 in Mill Valley, California.

    Could vaccine compliance be correlated with income level and elitism?

  • Novavax starts Ebola vaccine trial in humans Thursday, 12 Feb 2015 | 8:27 AM ET

    Feb 12- Novavax Inc has begun early-stage testing of its Ebola vaccine in humans, the company said, less than five months after entering the race to develop a shot for the deadly virus. Other potential vaccines include those being developed by a NewLink Genetics Corp and Merck& Co Inc collaboration and by Johnson& Johnson and Bavarian Nordic A/S.

  • University of Florida researchers reported findings from a two-year study using the diabetes drug metformin in mice and human blood cells in a laboratory setting in the journal Science Translational Medicine. The findings could become a new treatment option for lupus, for which there is no cure, according to a news release from the University of Florida.

  • Tech company wants to help hospitals save millions  Wednesday, 11 Feb 2015 | 11:50 AM ET

    Mark Slaughter, Cohealo Inc. founder and CEO, explains how his company is helping hospitals share underutilized medical equipment.

  • Linking 'docs-in-the-box' to antibiotic-resistance Tuesday, 10 Feb 2015 | 2:16 PM ET

    New studies underscore the human and financial tolls of antibiotic-resistant drugs, as well as how competition could be driving over-prescription.

  • New numbers from the CDC show 121 cases of measles so far in 2015. Details on the Senate's hearing, with CNBC's Meg Tirrell.

  • WASHINGTON, Feb 10- For the first time in 20 years, patients suffering from the eye disease glaucoma may soon have new treatments as several young companies look to shake up the $5.6 billion global market. No new class of medicine has been introduced since Pfizer Inc's N> Xalatan, known generically as latanoprost, in 1996.. The newcomers aim to disrupt...

  • *All-Achillion combination could rival Gilead, AbbVie treatments. Achillion's shares rose as much as 19 percent to $12.85 on Monday on investor's hopes that an all-Achillion combination could be as effective as Gilead's and AbbVie Inc's current therapies. The estimated $20 billion market for hepatitis C drugs has developed at a lightning pace in recent...

  • PARIS, Feb 9- Canada reported an outbreak of the highly pathogenic bird flu virus H5N1 in the province of British Columbia, the World Organisation for Animal Health said on Monday. The outbreak was detected on Feb. 2 in a backyard poultry flock in the province of British Columbia, where bird flu cases of the separate H5N2 strain had been reported in December, it said,...

  • Feb 9- Achillion Pharmaceuticals Inc said its experimental hepatitis C drug, when used in combination with Gilead Sciences Inc's Sovaldi, eradicated signs of the virus after six weeks of therapy, sending its shares up before the opening bell. If the combination of Sovaldi and Achillion's ACH-3102 continues to show this level of effectiveness, the treatment...

  • Drug price battles  Friday, 6 Feb 2015 | 3:19 PM ET

    Express Scripts chief medical officer Steve Miller, discusses pricing competition in drugs. Express Scripts signed a deal with AbbVie to exclusively carry its hep C drug.

  • Where'd the $115 million for ALS go?  Friday, 6 Feb 2015 | 2:41 PM ET

    CNBC's Meg Tirrell reports where the money raised in the ALS ice bucket challenge went.

  • US not doing well on childhood vaccinations: Expert Thursday, 5 Feb 2015 | 8:53 AM ET
    Miami Children's Hospital pediatrician Dr. Amanda Porro, M.D prepares to administer a measles vaccination to a child at the Miami Children's Hospital on January 28, 2015 in Miami, Florida.

    The World Health Organization reports that 113 countries have higher immunization rates than the United States for 1-year-olds.

  • US lagging in measles immunizations  Thursday, 5 Feb 2015 | 8:03 AM ET

    Ezekiel Emanuel, M.D., University of Pennsylvania, discusses the recent measles outbreak in the U.S. and the growing battle over vaccinations.

  • AstraZeneca posts loss; to buy Actavis lung unit Thursday, 5 Feb 2015 | 3:31 AM ET

    AstraZeneca reported a loss for the fourth quarter of 2014, but stressed that it was on track to return to growth by 2017.

  • GSK sales falls; firm upbeat on respiratory unit Wednesday, 4 Feb 2015 | 8:45 AM ET

    Shares of GlaxoSmithKline jumped on Wednesday, despite the company posting a 3 percent fall in full-year revenue.

  • Case closed on vaccine-autism debate: Doctor Wednesday, 4 Feb 2015 | 8:27 AM ET
    Vials of measles, mumps and rubella vaccine are displayed on a counter at a Walgreens Pharmacy on January 26, 2015 in Mill Valley, California.

    The scientific community has thoroughly debunked any association behind autism and vaccination, Dr. Scott Gottlieb tells CNBC.